Prosecution Insights
Last updated: November 04, 2026
Application No. 18/937,460

PHOTOSTABLE COMPOSITIONS COMPRISING PARA-ALKOXYL PHENYL SUBSTITUTED PROPENOIC ACID (APP) COPOLYMER DERIVATIVES

Non-Final OA §103§112§DOUBLEPATENT
Filed
Nov 05, 2024
Priority
Jul 07, 2016 — provisional 62/359,539 +4 more
Examiner
PURDY, KYLE A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Hallstar Beauty And Personal Care Innovations Company
OA Round
1 (Non-Final)
41%
Grant Probability
Moderate
1-2
OA Rounds
2y 2m
Est. Remaining
77%
With Interview

Examiner Intelligence

Grants 41% of resolved cases
41%
Career Allowance Rate
410 granted / 1002 resolved
-19.1% vs TC avg
Strong +36% interview lift
Without
With
+35.7%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
75 currently pending
Career history
1091
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
62.8%
+22.8% vs TC avg
§102
13.8%
-26.2% vs TC avg
§112
14.3%
-25.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1002 resolved cases

Office Action

§103 §112 §DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election Acknowledged Applicants’ election without traverse the species of block copolymer where the functional groups are A, C = CN; B, D-G = O; K, L = methyl; R1, R6 = H; and R, R2-R5, R5-R12 = methyl encompassing claims 21-24, 26-33 and 35-40 is acknowledged. The restriction is made final without traverse. It is noted that claims 25 and 34 have been withdrawn as these two claims include a provision that R9=R10 or R11=R12 but not both. The present election of species has R9=R10 and R11=R12 as the same which is contrary to the scope of these claims. As such, they have been withdrawn as being directed to nonelected subject matter. Applicants elected species is considered free of prior art and the Examiner has expanded their search. Claims 21-40 are pending, claims 25 and 34 are withdrawn and claims 21-24, 26-33 and 35-40 are presented for examination on the merits. The following rejections are made. Information Disclosure Statement The information disclosure statement (IDS) submitted on 11/5/2024 was considered by the examiner. Allowable Subject Matter Claim 22, 23, 24, 32 and 33 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 21, 26-31 and 35-40 is/are rejected under 35 U.S.C. 103 as being unpatentable over Bury et al. (US 2010/0266814), evidenced by Honeywell: Dielectric Constant Table (51 pgs). Bury describes a photoalignment composition comprising a) 0.001-20wt% of a photoreactive compound, e.g. coumarin (see [0195, 0196]; see instant claims 21, 28, 29, 37, 38 and 39), and b) 80-99.99wt% a copolymer that does not possess a photoalignment group, includes the monomer block: PNG media_image1.png 75 283 media_image1.png Greyscale and c) a solvent, e.g. cyclohexanone (see [0229, 0231]). The structure PNG media_image1.png 75 283 media_image1.png Greyscale (see [0294]) overlaps with instant Formula II: PNG media_image2.png 130 331 media_image2.png Greyscale where B = O, m =5, A=H, K = H, R = butyl and R2 = methyl (see instant claims 21 and 31). It is noted that instant claim 21 identifies K as being C1-C15 alkyl, but it is the difference between a methyl group and H is not chemically significant and one would expect similar properties for both compounds. See MPEP 2144.09(I). The selection of coumarin as a photoreactive compound would be expected to exhibit the claimed properties as it is a species contemplated by the instant claims as a compound that ‘develops within itself an excited state of energy when subjected to UV radiation.’ Regarding the concentration of the copolymer as recited by instant claims 26, 27 and 36 such concentrations would be adjustable according to the desired outcome. Although Bury teaches that the copolymer is present in an amount of 80-99.9wt%, Bury also teaches that their composition may be diluted (see [0227]). Thus, diluting Bury’s composition to a copolymer concentration of between 1-20wt% would been readily within the ability of an ordinary skilled person. See MPEP 2144.05(II)(A) that states that differences in concentration do not support patentability unless there is evidence indicating such differences as critical and that where the general conditions of a claim are taught in the prior art, it is not inventive to discover workable ranges by routine experimentation. As noted above, Bury’s composition solvent may include cyclohexanone which is an oily liquid solvent that has a dielectric constant of 18.2 (see page 12 of Honeywell evidence) (see instant claims 29 and 40). Regarding the provision that the composition “…may enhance protection of at least one polymer against UV radiation, the at least one polymer comprising polyvinyl chloride, polystyrene, low-density polyethylene…” as recited by instant claims 29 and 30, this is an intended use limitation as it described how the composition may be used, i.e. to potentially enhance protection of a polymer, but does not limit the composition itself. See MPEP 2111.02(II) regarding statements of intended use. As for the limitation that the composition be used “for coating a skin to protect the skin from oxidative stress caused by absorption of light having a wavelength in the wavelength range of about 280 nm to about 300 nm” as recited by instant claim 31, this is also an intended use limitation as it provides a potential avenue for how the composition can be used without further defining the composition claimed. As the obvious prior art composition would possess the same composition/structure, it could also theoretically be used as a coating for a skin to protect despite Bury not contemplating such a use. Aside from the modification of the copolymer discussed above, the major difference between Bury and the instant claims is that Bury does not teach the specific combination of components as claimed in a single embodiment. However, when a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious”. See MPEP 2141(I). Such a rationale is applicable in the present case. Therefore, the invention as a whole is prima facie obvious to one of ordinary skill in the art at the time the invention was filed, as evidenced by the references, especially in absence of evidence to the contrary. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim 21, 27, 29, 31 and 36 are rejected under 35 U.S.C. 112(b) as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor regards as the invention. Claim 21 provides structure: PNG media_image2.png 130 331 media_image2.png Greyscale but does not provide any limitation as to what functional groups A includes and fails to provide limitation to the extent of m and n. This claim is unclear as it does not fully define the structure being claimed. Claim 31 is rejected for the same deficiency. Claim 27 recites, “…wherein the block copolymer is present at a concentration comprising about 15% by weight, about 10% by weight, about 5% by weight, about 1% by weight, or a combination thereof, based on the total weight of the composition.” The inclusion of “combinations thereof” is confusing. How would one include “combinations” of weight percentages? Does this mean that the concentrations may be added together? In any regard, the Examiner is unclear on what exactly this limitation requires and how it is best to be understood. Claim 36 is rejected for the same deficiency. Claim 29 recites, “…wherein at least one of: the at least one photoactive compound is present at a concentration of about 0.000001% by weight to about 20% by weight, based on the total weight of the composition, the at least one photoactive compound is present at a concentration comprising about 15% by weight, about 10% by weight, about 5% by weight, about 1% by weight, about 0.5% by weight, about 0.1% by weight, or a combination thereof, based on the total weight of the composition…” This limitation is unclear because it provides two separate range limitations for the photoactive compound within the claim. In one range a concentration of 0.000001% is claimed, in the other a minimum of about 0.1% is claimed. It is not clear which range is limiting. The metes and bounds of the concentration of photoactive compound are not clearly defined. Clarification is requested. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy meanwhile (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b) Claims 21-40 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-37 of U.S. Patent No. 10,556,981. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the referenced patent are directed to composition/methods comprising a) a photoreactive compound that develops within itself an excited state energy when subjected to UV radiation, and b) a block copolymer comprising a plurality of blocks, at least one block having a structure according to Formula II: PNG media_image3.png 174 378 media_image3.png Greyscale . All other limitations are essentially identical to the compositions/methods recited by the claims. Claims 21-40 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-25 of U.S. Patent No. 11,098,149. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the patent are directed to composition/methods comprising a) a photoreactive compound that develops within itself an excited state energy when subjected to UV radiation, and b) a block copolymer comprising a plurality of blocks, at least one block having a structure according to Formula II: PNG media_image3.png 174 378 media_image3.png Greyscale . All other limitations are essentially identical to the compositions/methods recited by the claims. Claims 21-40 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 11,767,392. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the patent are directed to composition/methods comprising a) a photoreactive compound that develops within itself an excited state energy when subjected to UV radiation, and b) a block copolymer comprising a plurality of blocks, at least one block having a structure according to Formula II: PNG media_image3.png 174 378 media_image3.png Greyscale . All other limitations are essentially identical to the compositions recited by the claims. Claims 21-40 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-23 of U.S. Patent No. 12,162,972. Although the claims at issue are not identical, they are not patentably distinct from each other because the claims of the patent are directed to composition/methods comprising a) a photoreactive compound that develops within itself an excited state energy when subjected to UV radiation, and b) a block copolymer comprising a plurality of blocks, at least one block having a structure according to Formula II: PNG media_image3.png 174 378 media_image3.png Greyscale . All other limitations are essentially identical to the compositions recited by the claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KYLE A PURDY whose telephone number is (571)270-3504. The examiner can normally be reached from 9AM to 5PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bethany Barham, can be reached on 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). /KYLE A PURDY/Primary Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Nov 05, 2024
Application Filed
Oct 29, 2026
Non-Final Rejection mailed — §103, §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778134
COMPOSTABLE ANTI-MICROBIAL FILM AND METHOD OF APPLYING FILM TO PACKAGING
4y 2m to grant Granted Nov 03, 2026
Patent 12779008
PROCESS FOR PURIFICATION OF MITRAGYNINE
3y 6m to grant Granted Nov 03, 2026
Patent 12767635
LIPOXYGENASE INHIBITORS
4y 1m to grant Granted Oct 20, 2026
Patent 12765549
METHOD OF USING/APPLYING A KERATIN HYDROLYSIS PEPTIDE SOLUTION TO PROMOTE TOLERANCE OF SOYBEAN AND ITS GROWTH UNDER STRESS OF FLOODING
2y 5m to grant Granted Oct 20, 2026
Patent 12758677
MATERIALS AND METHODS FOR DEODORIZATION OF MAMMALIAN URINE
2y 6m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
41%
Grant Probability
77%
With Interview (+35.7%)
4y 2m (~2y 2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1002 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month